Nationwide Fund Advisors’s Immunogen Inc IMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-46,374
Closed -$355K 2309
2017
Q3
$355K Sell
46,374
-3,765
-8% -$25K ﹤0.01% 2358
2017
Q2
$356K Hold
50,139
﹤0.01% 2352
2017
Q1
$194K Sell
50,139
-7,244
-13% -$21.1K ﹤0.01% 2605
2016
Q4
$117K Hold
57,383
﹤0.01% 2821
2016
Q3
$154K Hold
57,383
﹤0.01% 2752
2016
Q2
$177K Buy
57,383
+1,999
+4% +$12.5K ﹤0.01% 2668
2016
Q1
$489K Sell
55,384
-1,667
-3% -$14.1K ﹤0.01% 2105
2015
Q4
$774K Buy
57,051
+1,189
+2% +$14.6K ﹤0.01% 1854
2015
Q3
$536K Hold
55,862
﹤0.01% 2074
2015
Q2
$803K Sell
55,862
-7,186
-11% -$78.9K ﹤0.01% 1991
2015
Q1
$564K Sell
63,048
-2,637
-4% -$19.1K ﹤0.01% 2179
2014
Q4
$401K Sell
65,685
-35,352
-35% -$323K ﹤0.01% 2314
2014
Q3
$1.07M Buy
101,037
+327
+0.3% +$3.7K ﹤0.01% 1788
2014
Q2
$1.19M Buy
100,710
+796
+0.8% +$9.99K ﹤0.01% 1760
2014
Q1
$1.49M Sell
99,914
-107
-0.1% -$1.69K 0.01% 1543
2013
Q4
$1.47M Sell
100,021
-1,805
-2% -$27.7K 0.01% 1643
2013
Q3
$1.73M Buy
101,826
+3,533
+4% +$62.1K 0.01% 1515
2013
Q2
$1.63M Buy
+98,293
New +$1.59M 0.01% 1412

Other funds holding IMGN

Nationwide Fund Advisors's IMGN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 46,374 shares — an estimated $355K sold.

Nationwide Fund Advisors first reported a position in IMGN in Q2 2013 and held it in 18 quarters. The position peaked at $1.73M in Q3 2013. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 46,374 Immunogen Inc shares in Q4 2017, an estimated $355K.
  • Nationwide Fund Advisors first reported a position in Immunogen Inc in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Immunogen Inc position peaked at $1.73M in Q3 2013.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.